Abstract
DNA
nanostructures
exhibit
versatile
geometries
and
possess
sophisticated
capabilities
not
found
in
other
nanomaterials.
They
serve
as
customizable
nanoplatforms
for
orchestrating
the
spatial
arrangement
of
molecular
components,
such
biomolecules,
antibodies,
or
synthetic
This
is
achieved
by
incorporating
oligonucleotides
into
design
nanostructure.
In
realm
drug
delivery
to
cancer
cells,
there
a
growing
interest
active
targeting
assays
enhance
efficacy
selectivity.
The
approach
involves
“key‐lock”
mechanism
where
carrier,
through
its
ligand,
recognizes
specific
receptors
on
tumor
facilitating
release
drugs.
Various
nanostructures,
including
origami,
Tetrahedral,
nanoflower,
cruciform,
nanostar,
nanocentipede,
nanococklebur,
can
traverse
lipid
layer
cell
membrane,
allowing
cargo
nucleus.
Aptamers,
easily
formed
vitro,
are
recognized
their
targeted
due
high
selectivity
targets
low
immunogenicity.
review
provides
comprehensive
overview
recent
advancements
formation
modification
aptamer‐modified
within
systems.
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Март 6, 2025
Synthetic
biology
and
nanotechnology
fusion
represent
a
transformative
approach
promoting
fundamental
clinical
biomedical
science
development.
In
SynBioNanoDesign,
biological
systems
are
reimagined
as
dynamic
programmable
materials
to
yield
engineered
nanomaterials
with
emerging
specific
functionalities.
This
review
elucidates
comprehensive
examination
of
synthetic
biology's
pivotal
role
in
advancing
for
targeted
drug
delivery
systems.
It
begins
exploring
the
synergy
between
nanotechnology,
then
highlights
current
landscape
applications.
Subsequently,
discusses
design
novel
informed
by
principles,
focusing
on
expounding
tools
potential
developing
advanced
nanomaterials.
Afterward,
research
advances
innovative
through
were
systematically
summarized,
emphasizing
integration
genetic
circuitry
program
nanomaterial
responses.
Furthermore,
challenges,
weaknesses
opportunities,
prospective
directions,
ethical
societal
implications
SynBioNanoDesign
elucidated.
Finally,
summarizes
impact
that
may
have
drug-delivery
technologies
future.
Advanced Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 21, 2025
Abstract
Osteoarthritis
(OA)
is
a
widespread
musculoskeletal
disorder
affecting
≈600
million
people
globally,
and
small
interfering
RNA
(siRNA)
therapy
shows
potential
in
targeting
OA
progression.
However,
the
efficient
targeted
delivery
of
siRNA
remains
major
challenge
due
to
issues
with
tissue
specificity
degradation
vivo.
In
this
study,
A
DNA
origami‐based
chondrocyte‐targeted
system
(OCS)
designed
for
OA‐affected
cartilage.
The
origami
engineered
load
signal
transducer
activator
transcription
3
(Stat3),
key
regulator
inflammation
cartilage
degradation,
functionalized
anti‐CD44
aptamers
selective
chondrocytes.
vitro,
effectively
delivers
diseased
chondrocytes,
silencing
matrix
metalloproteinases
expression
reducing
inflammation.
rat
models,
it
preserves
integrity,
promotes
regeneration,
mitigates
ECM
without
evident
side
effects.
These
findings
highlight
as
promising
platform
siRNA‐based
therapy,
offering
solution
challenges
delivery.
Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Июнь 2, 2025
Non-coding
RNAs
(ncRNAs)
are
crucial
molecules
that
do
not
encode
proteins
but
play
roles
in
regulating
various
biological
processes.
Recent
research
highlights
ncRNAs
only
control
gene
expression
within
cells
also
facilitate
intercellular
communication
via
exosomes
and
other
carriers.
This
function
is
vital
the
tumor
microenvironment
(TME).
Our
review
covers
structure
functions
of
different
ncRNAs,
such
as
microRNAs
(miRNAs),
long
non-coding
(lncRNAs),
circular
(circRNAs).
We
examine
how
these
influence
initiation
progression.
Additionally,
we
explore
their
role
promoting
growth
or
immune
evasion
by
modulating
TME.
The
potential
using
therapeutic
targets
biomarkers
for
clinical
use
discussed.
As
our
understanding
grows,
development
new
therapies
based
on
anticipated
to
offer
improved
treatment
options
cancer
patients.
